Covid, Moderna: “We will make universal annual respiratory vaccine”

A ‘3 in 1’ mRna vaccine, constantly updated, to be done every year to protect yourself from Covid-19, flu and respiratory syncytial virus (RSV) at the same time. It is “one of the pillars of Moderna’s strategy”, which aims to be “the first company to market an annual pan-respiratory booster vaccine”. This was announced by the American company, communicating the first phase 1 data on its experimental quadrivalent influenza at mRna and recalling that it already has phase 2/3 on an anti-Rsv vaccine, after the positive results obtained in phase 1. ” Respiratory infections are a leading cause of death globally, with around 3 million deaths per year – points out Moderna – About one million of these deaths occur each year due to respiratory infections in high and middle-income countries and respiratory infections are responsible for more deaths than colorectal cancer in high-income countries. The burden of respiratory diseases is greater in children under 5, adults over 65 and high-risk groups including pregnant women, immunocompromised people and cancer patients “. Hence the project for an annual universal respiratory vaccine, which “could create value for health systems”, highlights Moderna, thanks to greater “adherence, convenience (one injection instead of three) and reduced administration costs” .